Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?

Affiliations

¹ Pulmonary Department-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
² Oncology Department, University of Thessali, Larissa, Greece.
³ Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

Editorial

Paul Zarogoulidis et al. J Thorac Dis. 2017 Sep.

. 2017 Sep;9(9):2771-2773.

doi: 10.21037/jtd.2017.08.24.

¹ Pulmonary Department-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
² Oncology Department, University of Thessali, Larissa, Greece.
³ Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.
Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC. Lee CK, et al. J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17. J Thorac Oncol. 2017. PMID: 27765535

1. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013;5 Suppl 4:S389-96. - PMC - PubMed
1. Zarogoulidis P, Gaga M, Huang H, et al. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? Clin Transl Med 2017;6:6. 10.1186/s40169-017-0135-8 - DOI - PMC - PubMed
1. Zarogoulidis P, Rapti A, Sardeli C, et al. Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series. Respir Med Case Rep 2017;21:171-5. - PMC - PubMed
1. Alidousty C, Brandes D, Heydt C, et al. Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing. J Mol Diagn 2017. [Epub ahead of print]. 10.1016/j.jmoldx.2017.06.004 - DOI - PubMed
1. Remon J, Menis J, Hasan B, et al. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. Clin Lung Cancer 2017. [Epub ahead of print]. 10.1016/j.cllc.2017.02.005 - DOI - PubMed